To comprehensively characterize the clinical, laboratory, and histopathologic features of breast cancer patients receiving care according to local standards in Malawi.

In an effort to improve therapeutic options for treatment, this study will explore the use of research laboratory testing results to guide treatment decisions for difficult to treat Mycobacterium abscessus and other non-tuberculous mycobacteria (NTM) infections. Specific combinations of antibiotics will be tested in the laboratory, alone or in combination, to determine if those antibiotics could help with treatment of individual patients.

We aim to characterize work exposures and illness in Badin, North Carolina--the site of an aluminum smelting facility for nearly 100 years.

To widen the availability of obstetric ultrasound through technology

The purpose of this IRB approved Humanitarian Use of a device is to allow patients to be treated with LDL-Apheresis, using the LIPOSORBER® LA-15 system. This device is approved for adult and pediatric patients with Focal Segmental Glomeruloslerosis as a Humanitarian Use Device. Its effectiveness has not been demonstrated.

The purpose of this research study is to understand how the management of Patient Reported Outcomes (PROs) could help improve surgical care for patients undergoing chest surgeries. PROs are symptoms directly reported by patients through the completion of a survey.

Speak with Medicaid providers about the upcoming change to how providers are reimbursed for services

To determine the impact of visually disruptive modalities on postural control

1. Create a prospective cohort of well-phenotyped adult CD, UC and IBDU patients with serial clinical and patient-reported data collected throughout 12 months of Zymfentra (IFX -dyyb) therapy. 2. To determine clinical response and remission rates, course of stool calprotectin values and persistence of therapy with Zymfentra (IFX -dyyb) for induction and maintenance therapy. 3. Assess the correlation of various outcome measures in CD, UC or IBDU (short Crohn's disease activity index (sCDAI), Simple Clinical Colitis Activity Index (SCCAI), Urgency score, Fatigue,SIBDQ, PROMIS measures for depression, anxiety, and social satisfaction and work productivity and activity impairment. 4. Assess the effect of Zymfentra (IFX-dyyb) on patient reported fistula symptoms in patients with CD with pre-existing perianal fistulizing disease. 5. Assess persistence and need for dose escalation therapy of Zymfentra (IFX-dyyb). 6. Assessment of trough levels taken in the setting of standard of care before and after start of Zymfentra (IFX-dyyb).

This study is designed to assess the effect of AZD0780 compared with placebo in reducing the risk of major cardiovascular events (MACE)-PLUS in patients with established ASCVD or those at high risk for a first ASCVD event.